|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–40. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heukamp LC and Büttner R: Molecular
diagnostics in lung carcinoma for therapy stratification.
Pathologe. 31:22–28. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferlay J, Autier P, Boniol M, Heanue M,
Colombet M and Boyle P: Estimates of the cancer incidence and
mortality in Europe in 2006. Ann Oncol. 18:581–592. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
El-Nikhely N, Larzabal L, Seeger W, Calvo
A and Savai R: Tumor-stromal interactions in lung cancer: Novel
candidate targets for therapeutic intervention. Expert Opin
Investig Drugs. 21:1107–1122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Visser KE, Eichten A and Coussens LM:
Paradoxical roles of the immune system during cancer development.
Nat Rev Cancer. 6:24–37. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli
K, Andersen S, Sirera R, Camps C, Marinez I and Busund LT: The role
of tumor stroma in cancer progression and prognosis: Emphasis on
carcinoma-associated fibroblasts and non-small cell lung cancer. J
Thorac Oncol. 6:209–217. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dunér S, Lindman J Lopatko, Ansari D,
Gundewar C and Andersson R: Pancreatic cancer: The role of
pancreatic stellate cells in tumor progression. Pancreatology.
10:673–681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kalluri R: Basement membranes: Structure,
assembly and role in tumour angiogenesis. Nat Rev Cancer.
3:422–433. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Erkan M, Michalski CW, Rieder S,
Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H
and Kleeff J: The activated stroma index is a novel and independent
prognostic marker in pancreatic ductal adenocarcinoma. Clin
Gastroenterol Hepatol. 6:1155–1161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Erkan M, Kleeff J, Gorbachevski A, Reiser
C, Mitkus T, Esposito I, Giese T, Büchler MW, Giese NA and Friess
H: Periostin creates a tumor-supportive microenvironment in the
pancreas by sustaining fibrogenic stellate cell activity.
Gastroenterology. 132:1447–1464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kanno A, Satoh K, Masamune A, Hirota M,
Kimura K, Umino J, Hamada S, Satoh A, Egawa S, Motoi F, et al:
Periostin, secreted from stromal cells, has biphasic effect on cell
migration and correlates with the epithelial to mesenchymal
transition of human pancreatic cancer cells. Int J Cancer.
122:2707–2718. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morra L and Moch H: Periostin expression
and epithelial-mesenchymal transition in cancer: A review and an
update. Virchows Arch. 459:465–475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hong LZ, Wei XW, Chen JF and Shi Y:
Overexpression of periostin predicts poor prognosis in non-small
cell lung cancer. Oncol Lett. 6:1595–1603. 2013.PubMed/NCBI
|
|
17
|
Erkan M, Kleeff J, Esposito I, Giese T,
Ketterer K, Büchler MW, Giese NA and Friess H: Loss of BNIP3
expression is a late event in pancreatic cancer contributing to
chemoresistance and worsened prognosis. Oncogene. 24:4421–4432.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Michalski CW, Shi X, Reiser C, Fachinger
P, Zimmermann A, Büchler MW, Di Sebastiano P and Friess H:
Neurokinin-2 receptor levels correlate with intensity, frequency,
and duration of pain in chronic pancreatitis. Ann Surg.
246:786–793. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saville DJ: Multiple comparison
procedures: The practical solution. Am Stat. 44:174–180. 1990.
View Article : Google Scholar
|
|
20
|
Soltermann A, Tischler V, Arbogast S,
Braun J, Probst-Hensch N, Weder W, Moch H and Kristiansen G:
Prognostic significance of epithelial-mesenchymal and
mesenchymal-epithelial transition protein expression in non-small
cell lung cancer. Clin Cancer Res. 14:7430–7437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan W and Shao R: Transduction of a
mesenchyme-specific gene periostin into 293T cells induces cell
invasive activity through epithelial-mesenchymal transformation. J
Biol Chem. 281:19700–19708. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim CJ, Yoshioka N, Tambe Y, Kushima R,
Okada Y and Inoue H: Periostin is down-regulated in high grade
human bladder cancers and suppresses in vitro cell invasiveness and
in vivo metastasis of cancer cells. Int J Cancer. 117:51–58. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshioka N, Fuji S, Shimakage M, Kodama K,
Hakura A, Yutsudo M, Inoue H and Nojima H: Suppression of
anchorage-independent growth of human cancer cell lines by the
TRIF52/periostin/OSF-2 gene. Exp Cell Res. 279:91–99. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choi H, Sheng J, Gao D, Li F, Durrans A,
Ryu S, Lee SB, Narula N, Rafii S, Elemento O, et al: Transcriptome
analysis of individual stromal cell populations identifies
stroma-tumor crosstalk in mouse lung cancer model. Cell Rep.
10:1187–1201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yano T, Tanikawa S, Fujie T, Masutani M
and Horie T: Vascular endothelial growth factor expression and
neovascularisation in non-small cell lung cancer. Eur J Cancer.
36:601–609. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Giatromanolaki A, Koukourakis MI,
Theodossiou D, Barbatis K, O'Byrne K, Harris AL and Gatter KC:
Comparative evaluation of angiogenesis assessment with
anti-factor-VIII and anti-CD31 immunostaining in non-small cell
lung cancer. Clin Cancer Res. 3:2485–2492. 1997.PubMed/NCBI
|
|
27
|
Han H, Silverman JF, Santucci TS, Macherey
RS, d'Amato TA, Tung MY, Weyant RJ and Landreneau RJ: Vascular
endothelial growth factor expression in stage I non-small cell lung
cancer correlates with neoangiogenesis and a poor prognosis. Ann
Surg Oncol. 8:72–79. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koukourakis MI, Giatromanolaki A, O'Byrne
KJ, Whitehouse RM, Talbot DC, Gatter KC and Harris AL: Potential
role of bcl-2 as a suppressor of tumour angiogenesis in
non-small-cell lung cancer. Int J Cancer. 74:565–570. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sharma S, Sharma MC and Sarkar C:
Morphology of angiogenesis in human cancer: A conceptual overview,
histoprognostic perspective and significance of neoangiogenesis.
Histopathology. 46:481–489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Raica M, Cimpean AM and Ribatti D:
Angiogenesis in pre-malignant conditions. Eur J Cancer.
45:1924–1934. 2009. View Article : Google Scholar : PubMed/NCBI
|
